Cryo-EM structure-based discovery of etravirine as a specific inhibitor of PRMT5/pICln protein-protein interaction for prostate cancer treatment
Zhixia Chi, Xueyong Xu, Zhihang Shen, Xuehong Deng, Bennett D Elzey, Chenglong Li, Wen Jiang, Chang-Deng Hu · 2026
Read Cryo-EM structure-based discovery of etravirine as a specific inhibitor of PRMT5/pICln protein-protein interaction for prostate cancer treatment by Zhixia Chi, Xueyong Xu, Zhihang Shen, Xuehong Deng, Bennett D Elzey, Chenglong Li, Wen Jiang, Chang-Deng Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13556114.txt.
Description
Zhixia Chi and co-authors report a 2026 study on a new way to attack prostate cancer. The work centers on a protein called PRMT5, which is found at high levels in many cancers. In prostate cancer, the protein pairs with a partner called pICln and helps tumors grow.
Using a detailed image of the pair, the team found a fresh contact site where the two proteins meet. A computer search pointed to etravirine, a drug already in use for other care. Tests showed the drug breaks the pair apart. In cells and in mice, it slowed tumor growth and lowered levels of a key growth signal.
Catalog record
| CREATOR | Zhixia Chi, Xueyong Xu, Zhihang Shen, Xuehong Deng, Bennett D Elzey, Chenglong Li, Wen Jiang, Chang-Deng Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |